Minnesota SF 2645: Formulary Committee members with a potential conflict of interest participation in committee communications and discussions authorization provision, public comment process for recommendations to the Formulary Committee development by the commissioner of human services requirement provision, and Minnesota Rare Disease Advisory Council expertise sought by the Formulary Committee requirement provision

Status: Referred to Health and Human Services (as of 2025-03-17)

State: Minnesota · Session: 2025-2026 · Bill: SF 2645

Subjects: Committees, Drugs and Medicine, Health and Health Department

Sponsors: Boldon, Kupec, Lieske

View Minnesota SF 2645 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.